METABOLIC4
- Cagrilintide$45.00
Long-acting amylin and calcitonin receptor agonist. Investigated for appetite suppression, gastric emptying delay, and visceral fat reduction, with synergistic effects when combined with GLP-1 agonists.
- Retatrutide$120.00
Triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Investigated for aggressive visceral fat reduction and metabolic remodeling across multiple hormonal pathways.
- Semaglutide$45.00
GLP-1 receptor agonist for appetite regulation, gastric emptying delay, and glucose homeostasis. Broadly studied for weight reduction and cardiometabolic outcomes.
- Tirzepatide$85.00
Dual GIP and GLP-1 receptor agonist with a long-acting profile. Investigated for enhanced weight reduction and glycemic control beyond GLP-1 monotherapy.
RECOVERY1
- KLOW$100.00
Multi-peptide blend featuring GHK-Cu, BPC-157, TB-500, and KPV. Investigated for tissue repair, inflammation response, and recovery pathways.
LONGEVITY2
- MOTS-C$40.00
Mitochondrial-derived peptide encoded by mtDNA. Investigated for AMPK activation, insulin sensitivity, metabolic stress adaptation, and age-related decline in mitochondrial function.
- NAD+$60.00
Coenzyme central to cellular energy metabolism and DNA repair. Investigated for mitochondrial biogenesis, sirtuin activation, and attenuation of age-related decline in cellular function.
GH AXIS2
- Ipamorelin$25.00
Selective ghrelin receptor agonist triggering pulsatile GH release. Studied for muscle preservation and recovery with minimal impact on cortisol or prolactin.
- Tesamorelin$55.00
Stabilized synthetic GHRH analog signaling the pituitary for endogenous GH release. FDA-approved for visceral lipodystrophy; investigated for visceral fat reduction and body composition.